Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) FCF Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed FCF Margin for 12 consecutive years, with 185.9% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 95145.0% to 185.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 270.36% through Dec 2025, up 238805.0% year-over-year, with the annual reading at 270.36% for FY2025, 238805.0% up from the prior year.
  • FCF Margin for Q4 2025 was 185.9% at ImmunityBio, up from 212.46% in the prior quarter.
  • The five-year high for FCF Margin was 185.9% in Q4 2025, with the low at 730550.0% in Q1 2022.
  • Average FCF Margin over 5 years is 108328.07%, with a median of 38652.48% recorded in 2021.
  • The sharpest move saw FCF Margin plummeted -68195144bps in 2022, then soared 70184361bps in 2023.
  • Over 5 years, FCF Margin stood at 25543.59% in 2021, then crashed by -488bps to 150216.44% in 2022, then surged by 41bps to 88651.8% in 2023, then skyrocketed by 99bps to 1137.34% in 2024, then surged by 84bps to 185.9% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 185.9%, 212.46%, and 302.73% for Q4 2025, Q3 2025, and Q2 2025 respectively.